Geode Capital Management, LLC Exelixis, Inc. Transaction History

Geode Capital Management, LLC

$1.12 Trillion
Q2 2024

A detailed history of Geode Capital Management, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 5,166,204 shares of EXEL stock, worth $148 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

5,166,204

Previous 5,241,765 1.44%

Holding current value

$148 Million

Previous $124 Million 6.68%

% of portfolio

0.01%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$20.34 - $23.73 $1.54 Million - $1.79 Million	-75,561 Reduced 1.44%	5,166,204 $116 Million
Q1 2024 May 13, 2024	BUY	$20.17 - $23.93 $1.95 Million - $2.31 Million	96,447 Added 1.87%	5,241,765 $124 Million
Q4 2023 Feb 13, 2024	BUY	$19.25 - $24.13 $1.36 Million - $1.7 Million	70,573 Added 1.39%	5,145,318 $123 Million
Q3 2023 Nov 13, 2023	BUY	$19.04 - $22.74 $785,247 - $937,843	41,242 Added 0.82%	5,074,745 $111 Million
Q2 2023 Aug 11, 2023	BUY	$18.17 - $20.48 $4.82 Million - $5.44 Million	265,404 Added 5.57%	5,033,503 $96.2 Million
Q1 2023 May 15, 2023	BUY	$16.3 - $19.41 $3.29 Million - $3.92 Million	201,810 Added 4.42%	4,768,099 $92.5 Million
Q4 2022 Feb 13, 2023	BUY	$14.96 - $17.39 $3.42 Million - $3.98 Million	228,943 Added 5.28%	4,566,289 $73.2 Million
Q3 2022 Nov 14, 2022	BUY	$15.68 - $22.27 $1.17 Million - $1.66 Million	74,758 Added 1.75%	4,337,346 $68 Million
Q2 2022 Aug 12, 2022	SELL	$17.44 - $23.16 $193,706 - $257,238	-11,107 Reduced 0.26%	4,262,588 $88.7 Million
Q1 2022 May 13, 2022	BUY	$17.03 - $22.67 $2.67 Million - $3.56 Million	156,861 Added 3.81%	4,273,695 $96.9 Million
Q4 2021 Feb 11, 2022	BUY	$15.84 - $21.88 $1.74 Million - $2.4 Million	109,609 Added 2.74%	4,116,834 $75.3 Million
Q3 2021 Nov 12, 2021	BUY	$16.3 - $21.14 $553,955 - $718,442	33,985 Added 0.86%	4,007,225 $84.7 Million
Q2 2021 Aug 13, 2021	BUY	$17.95 - $25.56 $917,460 - $1.31 Million	51,112 Added 1.3%	3,973,240 $72.4 Million
Q1 2021 May 12, 2021	BUY	$20.53 - $25.22 $2.08 Million - $2.55 Million	101,180 Added 2.65%	3,922,128 $88.6 Million
Q4 2020 Feb 12, 2021	BUY	$18.39 - $24.8 $4.35 Million - $5.86 Million	236,344 Added 6.59%	3,820,948 $76.7 Million
Q3 2020 Nov 13, 2020	SELL	$20.67 - $26.94 $2.47 Million - $3.21 Million	-119,327 Reduced 3.22%	3,584,604 $87.6 Million
Q2 2020 Aug 13, 2020	BUY	$16.46 - $27.42 $1.4 Million - $2.33 Million	84,837 Added 2.34%	3,703,931 $87.9 Million
Q1 2020 May 14, 2020	BUY	$14.46 - $21.8 $1.98 Million - $2.99 Million	137,125 Added 3.94%	3,619,094 $62.3 Million
Q4 2019 Feb 13, 2020	BUY	$15.15 - $18.89 $1.6 Million - $2 Million	105,861 Added 3.14%	3,481,969 $61.4 Million
Q3 2019 Nov 12, 2019	BUY	$17.68 - $22.65 $724,031 - $927,562	40,952 Added 1.23%	3,376,108 $59.7 Million
Q2 2019 Aug 14, 2019	BUY	$18.93 - $24.75 $3.44 Million - $4.49 Million	181,560 Added 5.76%	3,335,156 $71.3 Million
Q1 2019 May 14, 2019	BUY	$19.6 - $24.76 $2.83 Million - $3.57 Million	144,142 Added 4.79%	3,153,596 $75.1 Million
Q4 2018 Feb 13, 2019	BUY	$13.65 - $21.8 $2.87 Million - $4.58 Million	210,181 Added 7.51%	3,009,454 $59.2 Million
Q3 2018 Nov 13, 2018	BUY	$15.87 - $22.4 $2.82 Million - $3.98 Million	177,653 Added 6.78%	2,799,273 $49.6 Million
Q2 2018 Aug 14, 2018	BUY	$18.56 - $22.45 $2.16 Million - $2.61 Million	116,110 Added 4.63%	2,621,620 $56.4 Million
Q1 2018 May 15, 2018	BUY	$22.15 - $31.89 $1.41 Million - $2.03 Million	63,668 Added 2.61%	2,505,510 $55.5 Million
Q4 2017 Feb 13, 2018	SELL	$24.23 - $30.93 $409,220 - $522,376	-16,889 Reduced 0.69%	2,441,842 $74.2 Million
Q3 2017 Nov 14, 2017	BUY	$23.35 - $29.24 $8.08 Million - $10.1 Million	346,184 Added 16.39%	2,458,731 $59.6 Million
Q2 2017 Aug 14, 2017	BUY	N/A	2,112,547	2,112,547 $52 Million

Others Institutions Holding EXEL

# of Institutions

466

Shares Held

239M

Call Options Held

2.04M

Put Options Held

1.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $9.25B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Exelixis, Inc. Transaction History